Drug Profile
PD 217014
Alternative Names: PD-217,014Latest Information Update: 12 Sep 2008
Price :
$50
*
At a glance
- Originator Pfizer
- Class Aminobutyric acids; Anti-inflammatories; Heterocyclic bicyclo compounds; Irritable bowel syndrome therapies; Urologics
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Irritable bowel syndrome; Overactive bladder; Postherpetic neuralgia
Most Recent Events
- 07 Jan 2005 Phase-II clinical trials in Overactive bladder in United Kingdom (unspecified route)
- 31 Jan 2004 Phase-II clinical trials in Irritable bowel syndrome in United Kingdom (unspecified route)